L3VLUP
ProSign in

ISRG · LLY in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

ISRGLLY
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • ISRG
  • LLY
0204060202120222023202420252026
Holders and value by quarter
QuarterISRGLLY
Q3 202020 holders, $19.6bn33 holders, $14.1bn
Q4 202019 holders, $21.4bn29 holders, $17.3bn
Q1 202126 holders, $18.3bn24 holders, $23.0bn
Q2 202133 holders, $23.2bn24 holders, $27.8bn
Q3 202131 holders, $23.9bn31 holders, $29.9bn
Q4 202134 holders, $26.0bn31 holders, $34.7bn
Q1 202227 holders, $21.0bn24 holders, $35.3bn
Q2 202235 holders, $13.0bn33 holders, $42.7bn
Q3 202232 holders, $11.1bn31 holders, $43.4bn
Q4 202226 holders, $15.6bn31 holders, $46.6bn
Q1 202332 holders, $14.4bn33 holders, $44.3bn
Q2 202333 holders, $20.2bn37 holders, $59.6bn
Q3 202340 holders, $17.0bn44 holders, $67.6bn
Q4 202338 holders, $20.0bn45 holders, $73.6bn
Q1 202432 holders, $23.6bn41 holders, $95.3bn
Q2 202429 holders, $27.0bn43 holders, $110bn
Q3 202431 holders, $28.4bn45 holders, $107bn
Q4 202434 holders, $30.3bn46 holders, $93.9bn
Q1 202542 holders, $28.7bn42 holders, $98.4bn
Q2 202539 holders, $30.6bn43 holders, $93.2bn
Q3 202541 holders, $23.6bn39 holders, $86.7bn
Q4 202541 holders, $35.8bn41 holders, $123bn
Q1 202640 holders, $29.0bn39 holders, $106bn
Q2 202635 holders, $24.5bn44 holders, $132bn
ISRG

Intuitive Surgical Inc

Holders
34
Reported value
$30.3bn
Buyers
15
Sellers
18

Breadth -3 among 94 comparable managers.

Medical devices and instrumentsHealthcare: biopharma and medtech · L3VLUPSurgical, medical and electromedical devices
LLY

Eli Lilly & Co

Holders
46
Reported value
$93.9bn
Buyers
24
Sellers
23

Breadth +1 among 94 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q4 2024

Among the 52 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only ISRG (6)

ARK Investment Management LLC, Arrowstreet Capital LP, Baillie Gifford & Co, Caxton Associates LLP, ExodusPoint Capital Management LP, Point72 Asset Management LP

Only LLY (18)

AQR Capital Management LLC, Brevan Howard Capital Management LP, Egerton Capital UK LLP, Eisler Capital Management Ltd, Freestone Grove Partners LP, Hudson Bay Capital Management LP, Jane Street Group LLC, Lone Pine Capital LLC, Polen Capital Management LLC, Renaissance Technologies LLC, Rokos Capital Management LLP, Schonfeld Strategic Advisors LLC, Soros Fund Management LLC, Squarepoint Ops LLC, Susquehanna International Group LLP, Tiger Global Management LLC, Verition Fund Management LLC, Voloridge Investment Management LLC

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →